Moreover, based on comparison between samples of non-cancerous liver tissue and NASH-related HCCs, we have identified tumor-related genes such as WHSC1 (Kuramoto et al. 2017), TRIM4, PRC1 and TUBA1B (Tian et al. 2020), whose expression levels are regulated by DNA methylation status as potential therapeutic targets in NASH-related HCCs. The gene discussed is NSD2; the disease is metabolic dysfunction-associated steatohepatitis.